An observational study in Psoriatic Arthritis, sponsored by Egymedicalpedia. Not yet recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-17.
Sponsored by Egymedicalpedia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Psoriatic with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Psoriatic · Egypt.
Among the 10 studies in Arthritis, Psoriatic with a site in Egypt, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 3rd registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →6 of the 10 studies in Arthritis, Psoriatic with a site in Egypt are open now. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
South Valley University · Sites in Egypt
Ages 18–50
Tanta University · Sites in Egypt
Ages 18–70
Ain Shams University · Sites in Egypt
Ages 20–50 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 20 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is below the median of 280 across 244 observational studies indexed under Arthritis, Psoriatic.
Median enrollment 53 across the 6 interventional studies, 143 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 6 most frequent:
Egymedicalpedia is the lead sponsor of 58 studies on the registry; 13 are open to participants now.
Egymedicalpedia has 1 study filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Psoriatic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
| NCT07046312Ain Shams UniversityRight Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level | 2027-04 |
| NCT07946497South Valley UniversityCAPN12 Gene Expression as a Molecular Discriminator | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Arthritis, Psoriatic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Psoriasis is one of the most common immunemediated chronic inflammatory skin disorders.
Psoriasis is one of the most common immunemediated chronic inflammatory skin disorders.
Beside genetic factors, several environmental factors such as injuries, infections, stress, drugs, and immune defect take part in autoimmune pathogenesis of the disease. In addition, it has been reported that some hormones may also have a role in the pathogenesis of psoriasis, due to their effects on keratinocytes proliferation.
Studies revealed that sex hormones manifest a variety of biological and immunological effects in the skin which modulate the natural course of psoriasis.
Approximately 20-30% of patients with psoriasis may also have psoriatic arthritis, which often causes significant musculoskeletal pain that significantly impairs quality of life (QoL).
Although sexual dysfunction is a common complaint, affecting 30 to 70% of psoriasis patients, few studies have analyzed the impact of psoriasis and psoriatic arthritis on quality of sexual life.
The female sexual function index (FSFI) is a self-reported questionnaire that has been validated in Arabic, and is used to measure a woman's sexual function over the course of the past four weeks.
A reliable and accurate way to assess female sexual function is the FSFI. The six domains of sexual function-desire, arousal, lubrication, orgasm, satisfaction, and pain-are assessed by the 19 questions in this questionnaire. The response is scored between 0 and 5 on a 5-point Likert scale.
Disease Activity in Psoriatic Arthritis (DAPSA) Helps measure disease activity in psoriatic arthritis based on joint symptoms, CRP and pain evaluation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
About 100 patient females suffering from Psoriatic arthritis and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients
Behavioral: The effect of psoriatic Arthritis
About 80 healthy control females
Behavioral: The effect of psoriatic Arthritis
to assess the frequency rates of sexual problems and associated factors in a cohort of married females with Psoriatic arthritis, and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients.
Also known as: Female Sexual dysfunction
Evaluation of female sexual function
To identify and understand the mechanisms of sexual problems in Psoriatic arthritis Patients in Qena university hospital.
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for Dec 2024, 6 months later.
Of 52 industry-sponsored observational studies under Arthritis, Psoriatic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 6 months is below that.
Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.